Hussein Abdelwahab: FDA Approves Asundexian as the First Factor XIa Inhibitor for Stroke Prevention
Hussein Abdelwahab, Hospital Pharmacist at Ibrahim Bin Hamad Obaid Allah Hospital, shared a post on LinkedIn about a recent article by Mukul Sharma et al, published in NEJM, adding:
“FDA APPROVED: Asundexian (Sunharbo) First in Class Factor XIa Inhibitor (November 9, 2026)
The U.S. FDA has approved Bayer’s asundexian (Sunharbo), the first oral selective Factor XIa inhibitor, for use with antiplatelet therapy to reduce the risk of recurrent stroke in adults following a recent non cardioembolic ischemic stroke (NIHSS low 15) or high risk TIA.
Why it matters: It targets the intrinsic pathway to reduce pathologic thrombosis while aiming to preserve natural hemostasis.
Key Evidence: OCEANIC STROKE (n equal 12,327)
Bullet 26 percent Relative Risk Reduction in ischemic stroke (6.2 percent asundexian plus antiplatelet vs. 8.4 percent placebo plus antiplatelet; HR 0.74; 95 plus CI 0.65 to 0.84; p low 0.0001).
Bullet Bleeding: Similar overall ISTH major bleeding rates between arms, though GI bleeding was more frequent with asundexian.
Clinical Practice Takeaways
Bullet Dose: 50 mg orally, once daily.
Bullet Caveat: NOT indicated for AFib or cardioembolic stroke prevention.
Bullet Caution: Not recommended in moderate to severe hepatic impairment (Child Pugh B or C).
A significant milestone in secondary stroke prevention. Careful patient selection and monitoring remain paramount.
References:
- FDA Approval Announcement (Nov 9, 2026).
- Sharma M, et al. N Engl J Med 2026 (OCEANIC STROKE).
- Bayer Sunharbo Prescribing Information (Nov 2026).”
Title: Bayer’s SUNHARBO® (asundexian), 50 mg tablets, the First and Only Factor XIa Inhibitor, Approved by the U.S. FDA to Reduce the Risk of Stroke in Adults With Recent Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack…
Authors: Mukul Sharma, Qiang Dong, Teruyuki Hirano, Scott E. Kasner, Jeffrey L. Saver, Jaime Masjuan, Andrew M. Demchuk, Charlotte Cordonnier, Daniel Bereczki, Georgios Tsivgoulis, Roland Veltkamp, Ivan Staikov, Hee-Joon Bae, Bruce C.V. Campbell, Andrea Zini, I-Hui Lee, Martin Kovar, Robert Mikulik, Robin Lemmens, José M. Ferro, Thompson Robinson, Hanne Christensen, Serefnur Ozturk, Ronen R. Leker, Peter Turcani, Agnieszka Slowik, Pablo Amaya, Fan Kee Hoo, Gian Marco De Marchis, Michael Knoflach, P.N. Sylaja, Jukka Putaala, Jonathan M. Coutinho, Bart van der Worp, Evija Miglane, Vaidas Matijošaitis, Arne G. Lindgren, Gisele Sampaio Silva, Else Charlotte Sandset, Saule T. Turuspekova, Pierre Amarenco, Kevin N. Sheth, Eric E. Smith, John W. Eikelboom, Raed A. Joundi, Karleen Schulze, M.Math., Lizhen Xu, Laura Heenan, Pablo Colorado, Lars Keller, Eva Muehlhofer, Christoph Neumann, Hardi Mundl, Ashkan Shoamanesh 
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 14, 2026, 13:31John Augoustides: Practical Anticoagulation Strategies for Cardiopulmonary Bypass in Patients with HIT
-
Nov 14, 2026, 13:09Antonio Galante: Management of Portal Vein Thrombosis
-
Nov 14, 2026, 12:47Yasmin Mohtasham Kia: Anticoagulation Knowledge and Treatment Outcomes in Patients With Mechanical Heart Valves
-
Nov 14, 2026, 12:37Nathan Connell: Annualized Bleeding Rate and the Future of Hemophilia A Treatment
-
Nov 14, 2026, 12:3210 Posts Not to Miss This Week
-
Nov 14, 2026, 11:28Kalyan Roy: A New Era in Thalassemia Treatment – FDA Approves Mitapivat
-
Nov 14, 2026, 11:24Can Iron Deficiency Really be Seen in Someone’s Face? – ASH
-
Nov 14, 2026, 11:19Lindsay Davison: Putting Childhood Anemia in the Spotlight with IronUp and Danone
-
Nov 14, 2026, 10:00Benjamin Tur: Putting Iron Deficiency Anemia on the Global Agenda at the Paris Peace Forum’s Child Summit